Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Roads End who wrote (1133)	3/7/2000 5:37:00 PM
From: SouthFloridaGuy	Read Replies (2) \| Respond to of 1605

Good analysis, Reichers...VASO will continue to go up if the pattern you state continues. Any and all dips our buying opps. I am late to VASO, picking it up yesterday in the high 6's. But still happy, nevertheless.

To: Roads End who wrote (1133)	3/8/2000 1:42:00 AM
From: swisstrader	Read Replies (1) \| Respond to of 1605

R: I know, I know (still fun)!...more news after the bell...stock traded like a pro last couple days: Tuesday March 7, 6:27 pm Eastern Time Company Press Release Further Results On EECP Therapy in Heart Failure to be Presented At ACC 2000 Scientific Sessions WESTBURY, N.Y.--(BUSINESS WIRE)--March 7, 2000--Vasomedical, Inc. (Nasdaq:VASO - news) announced today that a sub-study of the current investigation of EECP© therapy in heart failure patients will be presented at the 49th Scientific Sessions of the American College of Cardiology in Anaheim, CA. The oral presentation, ``Improvement in Left Ventricular Performance by Enhanced External Counterpulsation in Patients with Heart Failure', will be presented by John Gorcsan III, M.D., of the University of Pittsburgh, on Wednesday, March 15, at 9:30 AM. The study was conducted on eight patients with New York Heart Association (NYHA) Class II or III heart failure and an ejection fraction of <40%. Medical therapy was unaltered during the study. Following 35 hours of EECP© therapy, all patients showed significant increases in left ventricular function and ejection fraction. The authors concluded that EECP© therapy appears to be beneficial to left ventricular function in heart failure patients and may be a useful adjunct to medical therapy. ``We were pleased to note that the results of this study are consistent with other studies in this group of patients which were presented at the Heart Failure Society and AHA scientific sessions last fall,' commented D. Michael Deignan, President and CEO of Vasomedical. ``The study was undertaken to pursue a new indication for EECP© therapy in heart failure, and we are optimistic about the potential for EECP© therapy to help patients with heart failure.' According to American Heart Association statistics, there are 4.9 million patients in the U.S. with heart failure. With 400,000 new cases each year, heart failure is the single most frequent cause of hospitalization for people age 65 and older. Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting external counterpulsation systems based on the company's proprietary technology. EECP© is a registered trademark for Vasomedical's enhanced external counterpulsation system. This system is now in use at major medical centers, including the Mayo Clinic, the Ochsner Foundation Hospital and the Miami Heart Institute, as well as medical centers affiliated with Columbia University, the University of Pittsburgh, the University of California San Diego, the University of California San Francisco, and the University of Virginia. The company provides hospitals, clinics and private practices EECP© equipment, treatment guidance and a staff training and maintenance program to ensure optimal patient outcomes. Except for historical information contained in this release, the matters discussed are forward looking statements that involve risks and uncertainties. When used in this release, words such as ``anticipate,' ``believe,' ``estimate,' ``expect' and ``intend' and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.